Clinical Trials

GenitourinaryOther hematologic neoplasmSarcoma

1,000 enrolled

Osteosarcoma, Water Intoxication, Hematologic Neoplasms, Acute Kidney Injury, Drug-Related Side Effects and Adverse Reactions

NCT06363123 2024-04-15

Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

2,700 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06347614 2024-04-04

Two-step RP

Prostatic Neoplasms

NCT06344715 2024-04-03

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Phase 1 Unknown

78 enrolled

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06342323 2024-04-02

ONFM-SBRT

GastrointestinalGenitourinaryThoracic

57 enrolled

Carcinoma, Renal Cell, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms

NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Phase 1 Unknown

71 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06334406 2024-03-28

immunoBLAD

33 enrolled

Urinary Bladder Neoplasms

NCT05115812 2024-03-27

Renal Autotransplantation; Case Series

Carcinoma, Renal Cell, Hyperemia, Renal Nutcracker Syndrome

NCT04088968 2024-03-22

STRONG-CS

100 enrolled

GenitourinaryOther

Alcohol Drinking, Motor Activity, Obesity, Postoperative Complications, Smoking, Urologic Neoplasms, Risk Reduction Behavior, Malnutrition, Patient Preference

NCT01851018 2024-03-21

HyBraFi

Prostatic Neoplasms

NCT06322745 2024-03-21

Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy

Carcinoma, Renal Cell

NCT06324058 2024-03-21

Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC

190 enrolled

Urinary Bladder Neoplasms

NCT03795337 2024-03-20

HYPOSTAT-II

475 enrolled

Prostatic Neoplasms

NCT06317948 2024-03-20

MIKAPOCo

1,000 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT06321640 2024-03-20

POSITive

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

265 enrolled

Breast Neoplasms, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms

NCT06317298 2024-03-19

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

36 enrolled

Carcinoma, Renal Cell

NCT01802242 2024-03-18

Tumor TARGET Prostate Cancer

85 enrolled

Prostatic Neoplasms

NCT04997252 2024-03-18

An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer

50 enrolled

GastrointestinalGenitourinary

High-Risk and Oligometastatic Prostate Cancer

NCT05726136 2024-03-18

FC-VE

Phase 4 Unknown

60 enrolled

Neoplasms, Urologic Neoplasms, Colorectal Neoplasms

NCT04903873 2024-03-15

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Phase 1/2 Unknown

110 enrolled

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Prostatic Neoplasms

NCT05740488 2024-03-15

Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases

Prostate Cancer With ≤10 Bone Metastases

NCT06313775 2024-03-15

Comparison of Spinal Anesthesia and Spermatic Cord Block for Bilateral Orchiectomy

18 enrolled

Prostatic Neoplasms

NCT05671900 2024-03-08

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

70 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06298305 2024-03-07

QUANTIB

200 enrolled

Prostatic Neoplasms

NCT03580109 2024-03-06

THERMOEDEME